Epizyme (EPZM) Misses Q1 EPS by 71c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Epizyme (EPZM) Misses Q1 EPS by 71c

Epizyme Announces First Quarter 2015 Financial Results and Provides Corporate Update

April 28, 2015 4:01 PM EDT

Reacquired global rights to EPZ-6438 from Eisai, gaining full control of development, manufacturing and commercialization outside of Japan Completed successful public offering of shares of common stock, raising $130.7 million before expenses, including the April exercise of the underwriters option to purchase additional shares Completed enrollment in 800 mg BID and 1600 mg BID dose expansion cohorts in ongoing EPZ-6438 Phase 1 study Updated data from the dose escalation cohorts of the ongoing Phase 1 study of EPZ-6438 to be presented at the International Conference on Malignant Lymphoma on June 20,... More